Imipramine

Imipramine tablets and capsules are used to treat depression. Imipramine tablets are also used to prevent bedwetting in children. Imipramine is in a class of medications called tricyclic antidepressants. It treats depression by increasing the amounts of certain natural substances in the brain that are needed to maintain mental balance. There is not enough information to explain how imipramine prevents bedwetting.

Imipramine comes as a tablet and a capsule to take by mouth. When imipramine tablets or capsules are used to treat depression, they are usually taken one or more times a day and may be taken with or without food. When imipramine tablets are used to prevent bedwetting in children, they are usually taken one hour before bedtime. Children who wet the bed early in the evening may be given one dose in the mid-afternoon and another dose at bedtime. Try to take imipramine at around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take imipramine exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Your doctor may start you on a low dose of imipramine and gradually increase your dose.

It may take 1-3 weeks or longer for you to feel the full benefit of imipramine. Continue to take imipramine even if you feel well. Do not stop taking imipramine without talking to your doctor. Your doctor will probably want to decrease your dose gradually.

Imipramine is also used occasionally to treat eating disorders and panic disorders. Talk to your doctor about the possible risks of using this medication for your condition.

This medication may be prescribed for other uses. Ask your doctor or pharmacist for more information.

Before taking imipramine,

• tell your doctor and pharmacist if you are allergic to imipramine, any other medications, or any of the ingredients in imipramine tablets or capsules. Ask your doctor or pharmacist for a list of the ingredients.

• tell your doctor if you are taking a monoamine oxidase (MAO) inhibitor such as isocarboxazid (Marplan), linezolid (Zyvox), methylene blue, phenelzine (Nardil), selegiline (Eldepryl, Emsam, Zelapar), and tranylcypromine (Parnate), or if you have stopped taking an MAO inhibitor within the past 14 days. Your doctor will probably tell you not to take imipramine. If you stop taking imipramine, you should wait at least 14 days before you start to take an MAO inhibitor.

• tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: anticoagulants (blood thinners) such as warfarin (Coumadin, Jantoven); antihistamines; cimetidine (Tagamet); flecainide (Tambocor); levodopa (Sinemet, Larodopa); lithium (Eskalith, Lithobid); medication for high blood pressure, mental illness, nausea, seizures, Parkinson's disease, asthma, colds, or allergies; methylphenidate (Ritalin); muscle relaxants; propafenone (Rhythmol); quinidine; sedatives; selective serotonin reuptake inhibitors (SSRIs) such as citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac, Sarafem), fluvoxamine (Luvox), paroxetine (Paxil), and sertraline (Zoloft); sleeping pills; thyroid medications; and tranquilizers. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Your doctor may tell you not to take imipramine if you have taken fluoxetine in the past 5 weeks.

• tell your doctor if you have recently had a heart attack. Your doctor may tell you not to take imipramine.

• tell your doctor if you are being treated with electroshock therapy (procedure in which small electric shocks are administered to the brain to treat certain mental illnesses), and if you have or have ever had an enlarged prostate (a male reproductive gland), difficulty urinating, seizures, an overactive thyroid gland, or liver, kidney, or heart disease.

• tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. If you become pregnant while taking imipramine, call your doctor.

• if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking imipramine.

• you should know that this medication may make you drowsy. Do not drive a car or operate machinery until you know how this medication affects you.

• remember that alcohol can add to the drowsiness caused by this medication.

• tell your doctor if you use tobacco products. Cigarette smoking may decrease the effectiveness of this medication.

• plan to avoid unnecessary or prolonged exposure to sunlight and to wear protective clothing, sunglasses, and sunscreen. Imipramine may make your skin sensitive to sunlight.

• talk to your doctor about the risks and benefits of taking imipramine if you are 65 years of age or older. Older adults should not usually take imipramine because it is not as safe and effective as other medications that can be used to treat the same condition.

• you should know that imipramine may cause angle-closure glaucoma (a condition where the fluid is suddenly blocked and unable to flow out of the eye causing a quick, severe increase in eye pressure which may lead to a loss of vision). Talk to your doctor about having an eye examination before you start taking this medication. If you have nausea, eye pain, changes in vision, such as seeing colored rings around lights, and swelling or redness in or around the eye, call your doctor or get emergency medical treatment right away.

Unless your doctor tells you otherwise, continue your normal diet.

Take the missed dose as soon as you remember it. However, if it is almost time for your next dose, skip the missed dose and continue your regular dosing schedule.

• Imipramine may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

  • nausea

  • drowsiness

  • weakness or tiredness

  • excitement or anxiety

  • nightmares

  • dry mouth

  • skin more sensitive to sunlight than usual

  • changes in appetite or weight

  • constipation

  • difficulty urinating

  • frequent urination

  • changes in sex drive or ability

  • excessive sweating

• Some side effects can be serious. If you experience any of the following symptoms or those listed in the IMPORTANT WARNING or SPECIAL PRECAUTIONS sections, call your doctor immediately or get emergency medical treatment:

  • jaw, neck, and back muscle spasms

  • slow or difficult speech

  • shuffling walk

  • uncontrollable shaking of a part of the body

  • fever, sore throat, or other signs of infection

  • difficulty breathing or swallowing

  • severe rash

  • yellowing of the skin or eyes

  • irregular heartbeat

• If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

• Imipramine may cause other side effects. Tell your doctor if you have any unusual problems while you are taking this medication.

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom).

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Keep all appointments with your doctor.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug	Interaction
Moxifloxacin	Moxifloxacin The metabolism of Imipramine can be decreased when combined with Moxifloxacin.
Repaglinide	Repaglinide Imipramine may decrease the hypoglycemic activities of Repaglinide.
Insulin Glargine (rDNA origin) Injection	Insulin Glargine (rDNA origin) Injection The metabolism of Imipramine can be increased when combined with Insulin glargine.
Leflunomide	Leflunomide The serum concentration of Imipramine can be decreased when it is combined with Leflunomide.
Delavirdine	Delavirdine The metabolism of Imipramine can be decreased when combined with Delavirdine.
Nevirapine	Nevirapine The metabolism of Imipramine can be decreased when combined with Nevirapine.
Atorvastatin	Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Imipramine.
Dolasetron	Dolasetron The metabolism of Imipramine can be decreased when combined with Dolasetron.
Aminophylline	Aminophylline The metabolism of Aminophylline can be decreased when combined with Imipramine.
Anagrelide	Anagrelide The risk or severity of QTc prolongation can be increased when Imipramine is combined with Anagrelide.
Bisacodyl	Bisacodyl The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Imipramine.
Candesartan	Candesartan Imipramine may decrease the antihypertensive activities of Candesartan.
Cilostazol	Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Imipramine.
Clopidogrel	Clopidogrel The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Imipramine resulting in a loss in efficacy.
Diphenoxylate	Diphenoxylate The risk or severity of adverse effects can be increased when Imipramine is combined with Diphenoxylate.
Erythromycin and Sulfisoxazole	Erythromycin and Sulfisoxazole The serum concentration of Imipramine can be increased when it is combined with Erythromycin.
Estrogen and Progestin (Oral Contraceptives)	Estrogen and Progestin (Oral Contraceptives) The metabolism of Conjugated estrogens can be decreased when combined with Imipramine.
Fenofibrate	Fenofibrate The metabolism of Imipramine can be decreased when combined with Fenofibrate.
Guanfacine	Guanfacine Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Magnesium Hydroxide	Magnesium Hydroxide Imipramine may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Magnesium Oxide	Magnesium Oxide The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Imipramine.
Methylergonovine	Methylergonovine The risk or severity of hypertension can be increased when Methylergometrine is combined with Imipramine.
Miglitol	Miglitol Imipramine may decrease the hypoglycemic activities of Miglitol.
Mycophenolate	Mycophenolate Imipramine may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.
Naratriptan	Naratriptan The risk or severity of adverse effects can be increased when Imipramine is combined with Naratriptan.
Olsalazine	Olsalazine Imipramine may decrease the excretion rate of Olsalazine which could result in a higher serum level.
Paregoric	Paregoric The risk or severity of adverse effects can be increased when Morphine is combined with Imipramine.
Penbutolol	Penbutolol The metabolism of Imipramine can be decreased when combined with Acebutolol.
Pentazocine	Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Imipramine.
Polyethylene glycol-electrolyte solution (PEG-ES)	Polyethylene glycol-electrolyte solution (PEG-ES) The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Imipramine.
Potassium	Potassium Potassium may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy.
Prednisone	Prednisone Imipramine may decrease the excretion rate of Prednisone which could result in a higher serum level.
Psyllium	Psyllium The therapeutic efficacy of Plantago seed can be decreased when used in combination with Imipramine.
Ranitidine	Ranitidine The metabolism of Ranitidine can be decreased when combined with Imipramine.
Reserpine	Reserpine The serum concentration of Reserpine can be increased when it is combined with Imipramine.
Rizatriptan	Rizatriptan Rizatriptan may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Sumatriptan	Sumatriptan Sumatriptan may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Tacrolimus	Tacrolimus The serum concentration of Imipramine can be increased when it is combined with Tacrolimus.
Tizanidine	Tizanidine The serum concentration of Tizanidine can be increased when it is combined with Imipramine.
Triamcinolone	Triamcinolone The metabolism of Imipramine can be increased when combined with Triamcinolone.
Zolmitriptan	Zolmitriptan The metabolism of Zolmitriptan can be decreased when combined with Imipramine.
Ampicillin Injection	Ampicillin Injection Ampicillin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Doxycycline Injection	Doxycycline Injection Doxycycline may decrease the excretion rate of Imipramine which could result in a higher serum level.
Famotidine Injection	Famotidine Injection The metabolism of Imipramine can be decreased when combined with Famotidine.
Fluconazole Injection	Fluconazole Injection The serum concentration of Imipramine can be increased when it is combined with Fluconazole.
Foscarnet Injection	Foscarnet Injection Foscarnet may decrease the excretion rate of Imipramine which could result in a higher serum level.
Hydromorphone Injection	Hydromorphone Injection The risk or severity of adverse effects can be increased when Hydromorphone is combined with Imipramine.
Interferon Beta-1b Injection	Interferon Beta-1b Injection The metabolism of Imipramine can be decreased when combined with Interferon beta-1b.
Interferon Gamma-1b Injection	Interferon Gamma-1b Injection The metabolism of Imipramine can be decreased when combined with Interferon gamma-1b.
Levofloxacin Injection	Levofloxacin Injection The metabolism of Imipramine can be decreased when combined with Levofloxacin.
Meperidine Injection	Meperidine Injection The metabolism of Imipramine can be decreased when combined with Meperidine.
Metoclopramide Injection	Metoclopramide Injection The risk or severity of sedation can be increased when Metoclopramide is combined with Imipramine.
Metronidazole Injection	Metronidazole Injection The risk or severity of QTc prolongation can be increased when Imipramine is combined with Metronidazole.
Morphine Injection	Morphine Injection The risk or severity of adverse effects can be increased when Morphine is combined with Imipramine.
Pamidronate Injection	Pamidronate Injection Pamidronic acid may decrease the excretion rate of Imipramine which could result in a higher serum level.
Vancomycin Injection	Vancomycin Injection Imipramine may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Altretamine	Altretamine Amphetamine may decrease the sedative and stimulatory activities of Imipramine.
Cefuroxime	Cefuroxime Cefuroxime may decrease the excretion rate of Imipramine which could result in a higher serum level.
Cyclosporine	Cyclosporine The metabolism of Imipramine can be decreased when combined with Cyclosporine.
Ondansetron	Ondansetron The metabolism of Ondansetron can be decreased when combined with Imipramine.
Granisetron	Granisetron The risk or severity of QTc prolongation can be increased when Imipramine is combined with Granisetron.
Torsemide	Torsemide Imipramine may increase the excretion rate of Torasemide which could result in a lower serum level and potentially a reduction in efficacy.
Alosetron	Alosetron The metabolism of Imipramine can be decreased when combined with Alosetron.
Dofetilide	Dofetilide The risk or severity of QTc prolongation can be increased when Imipramine is combined with Dofetilide.
Entacapone	Entacapone The metabolism of Imipramine can be decreased when combined with Entacapone.
Eprosartan	Eprosartan Imipramine may decrease the antihypertensive activities of Eprosartan.
Hydroxychloroquine	Hydroxychloroquine The metabolism of Imipramine can be decreased when combined with Hydroxychloroquine.
Meloxicam	Meloxicam Imipramine may decrease the excretion rate of Meloxicam which could result in a higher serum level.
Oxcarbazepine	Oxcarbazepine The metabolism of Imipramine can be decreased when combined with Oxcarbazepine.
Pantoprazole	Pantoprazole The metabolism of Imipramine can be decreased when combined with Pantoprazole.
Telmisartan	Telmisartan The metabolism of Imipramine can be decreased when combined with Telmisartan.
Temozolomide	Temozolomide Imipramine may decrease the excretion rate of Temozolomide which could result in a higher serum level.
Zaleplon	Zaleplon Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Anakinra	Anakinra The metabolism of Imipramine can be increased when combined with Anakinra.
Desloratadine	Desloratadine Desloratadine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Linezolid	Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Imipramine.
Rivastigmine	Rivastigmine The therapeutic efficacy of Imipramine can be decreased when used in combination with Rivastigmine.
Trimipramine	Trimipramine Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trimipramine.
Etanercept Injection	Etanercept Injection The metabolism of Imipramine can be increased when combined with Etanercept.
Glycopyrrolate	Glycopyrrolate The risk or severity of adverse effects can be increased when Imipramine is combined with Glycopyrronium.
Modafinil	Modafinil The metabolism of Imipramine can be decreased when combined with Modafinil.
Perindopril	Perindopril Imipramine may decrease the antihypertensive activities of Perindopril.
Tenofovir	Tenofovir Tenofovir may decrease the excretion rate of Imipramine which could result in a higher serum level.
Choline Magnesium Trisalicylate	Choline Magnesium Trisalicylate Imipramine may decrease the excretion rate of Choline magnesium trisalicylate which could result in a higher serum level.
Sirolimus	Sirolimus The metabolism of Sirolimus can be decreased when combined with Imipramine.
Dutasteride	Dutasteride The risk or severity of hypertension can be increased when Imipramine is combined with Dutasteride.
Epinephrine Injection	Epinephrine Injection Imipramine may increase the vasopressor activities of Epinephrine.
Eplerenone	Eplerenone Imipramine may increase the excretion rate of Eplerenone which could result in a lower serum level and potentially a reduction in efficacy.
Escitalopram	Escitalopram The risk or severity of serotonin syndrome can be increased when Imipramine is combined with Escitalopram.
Olmesartan	Olmesartan Imipramine may decrease the antihypertensive activities of Olmesartan.
Zonisamide	Zonisamide The serum concentration of Imipramine can be increased when it is combined with Zonisamide.
Adalimumab Injection	Adalimumab Injection The metabolism of Imipramine can be increased when combined with Adalimumab.
Aripiprazole	Aripiprazole Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.
Atomoxetine	Atomoxetine The metabolism of Atomoxetine can be decreased when combined with Imipramine.
Dexmethylphenidate	Dexmethylphenidate The serum concentration of Imipramine can be increased when it is combined with Dexmethylphenidate.
Atazanavir	Atazanavir Atazanavir may decrease the excretion rate of Imipramine which could result in a higher serum level.
Almotriptan	Almotriptan The metabolism of Imipramine can be decreased when combined with Almotriptan.
Eletriptan	Eletriptan The metabolism of Imipramine can be decreased when combined with Eletriptan.
Mefloquine	Mefloquine The metabolism of Imipramine can be decreased when combined with Mefloquine.
Polyethylene Glycol 3350	Polyethylene Glycol 3350 The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Imipramine.
Vardenafil	Vardenafil The serum concentration of Imipramine can be increased when it is combined with Vardenafil.
Alfuzosin	Alfuzosin Alfuzosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine.
Aprepitant	Aprepitant The metabolism of Imipramine can be decreased when combined with Aprepitant.
Emtricitabine	Emtricitabine Imipramine may decrease the excretion rate of Emtricitabine which could result in a higher serum level.
Interferon Beta-1a Subcutaneous Injection	Interferon Beta-1a Subcutaneous Injection The metabolism of Imipramine can be decreased when combined with Interferon beta-1a.
Memantine	Memantine The metabolism of Imipramine can be decreased when combined with Memantine.
Tegaserod	Tegaserod The metabolism of Imipramine can be decreased when combined with Tegaserod.
Tadalafil	Tadalafil The risk or severity of hypotension, dyspepsia, and headache can be increased when Imipramine is combined with Tadalafil.
Frovatriptan	Frovatriptan The metabolism of Frovatriptan can be decreased when combined with Imipramine.
Gemifloxacin	Gemifloxacin The metabolism of Imipramine can be decreased when combined with Gemifloxacin.
Progesterone	Progesterone The metabolism of Imipramine can be decreased when combined with Progesterone.
Apomorphine Injection	Apomorphine Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Apomorphine.
Infliximab Injection	Infliximab Injection The metabolism of Imipramine can be increased when combined with Infliximab.
Protriptyline	Protriptyline The metabolism of Imipramine can be decreased when combined with Protriptyline.
Rifaximin	Rifaximin The metabolism of Imipramine can be increased when combined with Rifaximin.
Duloxetine	Duloxetine The risk or severity of orthostatic hypotension and syncope can be increased when Imipramine is combined with Duloxetine.
Norethindrone	Norethindrone The metabolism of Norethisterone can be increased when combined with Imipramine.
Tinidazole	Tinidazole Imipramine may decrease the excretion rate of Tinidazole which could result in a higher serum level.
Trospium	Trospium The metabolism of Trospium can be decreased when combined with Imipramine.
Bosentan	Bosentan Imipramine may decrease the antihypertensive activities of Bosentan.
Cefditoren	Cefditoren Imipramine may decrease the excretion rate of Cefdinir which could result in a higher serum level.
Cinacalcet	Cinacalcet The metabolism of Cinacalcet can be decreased when combined with Imipramine.
Cyanocobalamin Injection	Cyanocobalamin Injection Hydroxocobalamin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Erlotinib	Erlotinib The metabolism of Imipramine can be decreased when combined with Erlotinib.
Eszopiclone	Eszopiclone The risk or severity of CNS depression can be increased when Imipramine is combined with Eszopiclone.
Ganciclovir	Ganciclovir Imipramine may decrease the excretion rate of Ganciclovir which could result in a higher serum level.
Insulin Aspart (rDNA Origin) Injection	Insulin Aspart (rDNA Origin) Injection Imipramine may decrease the hypoglycemic activities of Insulin aspart.
Ribavirin	Ribavirin Imipramine may decrease the excretion rate of Ribavirin which could result in a higher serum level.
Solifenacin	Solifenacin The metabolism of Imipramine can be decreased when combined with Solifenacin.
Valganciclovir	Valganciclovir Imipramine may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
Voriconazole	Voriconazole The metabolism of Imipramine can be decreased when combined with Voriconazole.
Adefovir	Adefovir Adefovir may decrease the excretion rate of Imipramine which could result in a higher serum level.
Dextroamphetamine	Dextroamphetamine Amphetamine may decrease the sedative and stimulatory activities of Imipramine.
Entecavir	Entecavir The metabolism of Entecavir can be decreased when combined with Imipramine.
Peginterferon Alfa-2a Injection	Peginterferon Alfa-2a Injection The metabolism of Imipramine can be decreased when combined with Peginterferon alfa-2a.
Peginterferon Alfa-2b (PEG-Intron)	Peginterferon Alfa-2b (PEG-Intron) The serum concentration of Imipramine can be increased when it is combined with Peginterferon alfa-2b.
Pramlintide Injection	Pramlintide Injection The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Imipramine.
Sodium Oxybate	Sodium Oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Exenatide Injection	Exenatide Injection Imipramine may decrease the hypoglycemic activities of Exenatide.
Ibandronate	Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Imipramine.
Isocarboxazid	Isocarboxazid Imipramine may increase the serotonergic activities of Isocarboxazid.
Ramelteon	Ramelteon The metabolism of Imipramine can be decreased when combined with Ramelteon.
Darifenacin	Darifenacin The metabolism of Darifenacin can be decreased when combined with Imipramine.
Fentanyl	Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Imipramine.
Pregabalin	Pregabalin The therapeutic efficacy of Imipramine can be increased when used in combination with Pregabalin.
Deferasirox	Deferasirox The serum concentration of Imipramine can be increased when it is combined with Deferasirox.
Phenylephrine	Phenylephrine Imipramine may increase the vasopressor activities of Phenylephrine.
Tipranavir	Tipranavir The metabolism of Imipramine can be decreased when combined with Tipranavir.
Felbamate	Felbamate The metabolism of Imipramine can be decreased when combined with Felbamate.
Insulin Detemir (rDNA Origin) Injection	Insulin Detemir (rDNA Origin) Injection Imipramine may decrease the hypoglycemic activities of Insulin detemir.
Ranolazine	Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Imipramine.
Abatacept Injection	Abatacept Injection The metabolism of Imipramine can be increased when combined with Abatacept.
Rasagiline	Rasagiline Rasagiline may increase the serotonergic activities of Imipramine.
Imatinib	Imatinib The metabolism of Imipramine can be decreased when combined with Imatinib.
Sitagliptin	Sitagliptin Imipramine may decrease the hypoglycemic activities of Sitagliptin.
Varenicline	Varenicline The excretion of Varenicline can be decreased when combined with Imipramine.
Gefitinib	Gefitinib The metabolism of Imipramine can be decreased when combined with Gefitinib.
Albuterol	Albuterol The risk or severity of QTc prolongation can be increased when Imipramine is combined with Salbutamol.
Paliperidone	Paliperidone Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Bortezomib	Bortezomib The metabolism of Imipramine can be decreased when combined with Bortezomib.
Clofarabine Injection	Clofarabine Injection The serum concentration of Clofarabine can be increased when it is combined with Imipramine.
Insulin Glulisine (rDNA origin) Injection	Insulin Glulisine (rDNA origin) Injection The metabolism of Imipramine can be increased when combined with Insulin glulisine.
Lubiprostone	Lubiprostone Imipramine may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
Oxaliplatin Injection	Oxaliplatin Injection The serum concentration of Oxaliplatin can be increased when it is combined with Imipramine.
Posaconazole	Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Imipramine.
Primaquine	Primaquine The metabolism of Imipramine can be decreased when combined with Primaquine.
Aliskiren	Aliskiren Imipramine may decrease the antihypertensive activities of Aliskiren.
Bismuth Subsalicylate	Bismuth Subsalicylate Imipramine may increase the neurotoxic activities of Bismuth subsalicylate.
Pemetrexed Injection	Pemetrexed Injection Imipramine may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
Dimenhydrinate	Dimenhydrinate Dimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Lisdexamfetamine	Lisdexamfetamine Lisdexamfetamine may decrease the sedative and stimulatory activities of Imipramine.
Nabilone	Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Vorinostat	Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Imipramine.
Sorafenib	Sorafenib The metabolism of Sorafenib can be decreased when combined with Imipramine.
Sunitinib	Sunitinib The metabolism of Sunitinib can be decreased when combined with Imipramine.
Dronabinol	Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Lapatinib	Lapatinib The serum concentration of Lapatinib can be increased when it is combined with Imipramine.
Levocetirizine	Levocetirizine Levocetirizine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Pegaptanib Injection	Pegaptanib Injection Imipramine may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
Dasatinib	Dasatinib The metabolism of Dasatinib can be decreased when combined with Imipramine.
Mexiletine	Mexiletine The metabolism of Imipramine can be decreased when combined with Mexiletine.
Armodafinil	Armodafinil The metabolism of Imipramine can be decreased when combined with Armodafinil.
Azacitidine Injection	Azacitidine Injection Imipramine may decrease the excretion rate of Azacitidine which could result in a higher serum level.
Paclitaxel (with polyoxyethylated castor oil) Injection	Paclitaxel (with polyoxyethylated castor oil) Injection The therapeutic efficacy of Castor oil can be decreased when used in combination with Imipramine.
Temsirolimus	Temsirolimus The metabolism of Temsirolimus can be decreased when combined with Imipramine.
Lenalidomide	Lenalidomide Imipramine may decrease the excretion rate of Lenalidomide which could result in a higher serum level.
Nilotinib	Nilotinib The metabolism of Imipramine can be decreased when combined with Nilotinib.
Toremifene	Toremifene The serum concentration of Toremifene can be increased when it is combined with Imipramine.
Budesonide	Budesonide Imipramine may decrease the excretion rate of Budesonide which could result in a higher serum level.
Chloramphenicol Injection	Chloramphenicol Injection The metabolism of Imipramine can be decreased when combined with Chloramphenicol.
Desmopressin	Desmopressin The risk or severity of hyponatremia and water intoxication can be increased when Imipramine is combined with Desmopressin.
Betaine	Betaine The therapeutic efficacy of Imipramine can be decreased when used in combination with Glycine betaine.
OnabotulinumtoxinA Injection	OnabotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Botulinum toxin type A.
RimabotulinumtoxinB Injection	RimabotulinumtoxinB Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Botulinum Toxin Type B.
Doripenem Injection	Doripenem Injection Imipramine may decrease the excretion rate of Doripenem which could result in a higher serum level.
Etravirine	Etravirine The serum concentration of Etravirine can be decreased when it is combined with Imipramine.
Arsenic Trioxide Injection	Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Imipramine.
Desvenlafaxine	Desvenlafaxine The metabolism of Desvenlafaxine can be decreased when combined with Imipramine.
Cevimeline	Cevimeline The metabolism of Imipramine can be decreased when combined with Cevimeline.
Nebivolol	Nebivolol The metabolism of Imipramine can be decreased when combined with Nebivolol.
Tretinoin	Tretinoin The metabolism of Tretinoin can be decreased when combined with Imipramine.
Bendamustine Injection	Bendamustine Injection The metabolism of Bendamustine can be decreased when combined with Imipramine.
Flecainide	Flecainide The metabolism of Flecainide can be decreased when combined with Imipramine.
Certolizumab Injection	Certolizumab Injection The metabolism of Imipramine can be increased when combined with Certolizumab pegol.
Irinotecan Injection	Irinotecan Injection The metabolism of Irinotecan can be decreased when combined with Imipramine.
Daptomycin Injection	Daptomycin Injection Daptomycin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Praziquantel	Praziquantel The metabolism of Praziquantel can be decreased when combined with Imipramine.
Methylnaltrexone Injection	Methylnaltrexone Injection Imipramine may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
Rufinamide	Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Imipramine.
Silodosin	Silodosin Silodosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine.
Midazolam	Midazolam Midazolam may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Naltrexone Injection	Naltrexone Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Naltrexone.
Dexrazoxane Injection	Dexrazoxane Injection Dexrazoxane may decrease the excretion rate of Imipramine which could result in a higher serum level.
Eltrombopag	Eltrombopag The metabolism of Eltrombopag can be decreased when combined with Imipramine.
Milnacipran	Milnacipran The risk or severity of adverse effects can be increased when Imipramine is combined with Milnacipran.
Dexlansoprazole	Dexlansoprazole The metabolism of Imipramine can be decreased when combined with Dexlansoprazole.
Plerixafor Injection	Plerixafor Injection Imipramine may decrease the excretion rate of Plerixafor which could result in a higher serum level.
Sodium Phosphate	Sodium Phosphate The risk or severity of seizure can be increased when Imipramine is combined with Sodium phosphate, monobasic.
Fesoterodine	Fesoterodine The metabolism of Imipramine can be decreased when combined with Fesoterodine.
Degarelix Injection	Degarelix Injection The risk or severity of QTc prolongation can be increased when Degarelix is combined with Imipramine.
Betaxolol	Betaxolol The metabolism of Imipramine can be decreased when combined with Betaxolol.
Iloperidone	Iloperidone Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Iloperidone.
Prasugrel	Prasugrel The metabolism of Prasugrel can be decreased when combined with Imipramine.
Lacosamide	Lacosamide The metabolism of Imipramine can be decreased when combined with Lacosamide.
Everolimus	Everolimus The metabolism of Imipramine can be decreased when combined with Everolimus.
Tolvaptan (low blood sodium)	Tolvaptan (low blood sodium) Tolvaptan may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy.
Dronedarone	Dronedarone Dronedarone may increase the QTc-prolonging activities of Imipramine.
AbobotulinumtoxinA Injection	AbobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Botulinum toxin type A.
Pralatrexate Injection	Pralatrexate Injection Imipramine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Palonosetron Injection	Palonosetron Injection The metabolism of Imipramine can be decreased when combined with Palonosetron.
Saxagliptin	Saxagliptin Imipramine may decrease the hypoglycemic activities of Saxagliptin.
Telavancin Injection	Telavancin Injection The risk or severity of QTc prolongation can be increased when Imipramine is combined with Telavancin.
Romidepsin Injection	Romidepsin Injection The risk or severity of QTc prolongation can be increased when Imipramine is combined with Romidepsin.
Tapentadol	Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Topotecan	Topotecan Imipramine may decrease the excretion rate of Topotecan which could result in a higher serum level.
Golimumab Injection	Golimumab Injection The metabolism of Imipramine can be increased when combined with Golimumab.
Pazopanib	Pazopanib The metabolism of Imipramine can be decreased when combined with Pazopanib.
Asenapine	Asenapine Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Asenapine.
Vigabatrin	Vigabatrin Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Albendazole	Albendazole The metabolism of Albendazole can be decreased when combined with Imipramine.
Oxymorphone	Oxymorphone The metabolism of Imipramine can be decreased when combined with Oxymorphone.
Liraglutide Injection	Liraglutide Injection Imipramine may decrease the hypoglycemic activities of Liraglutide.
Tocilizumab Injection	Tocilizumab Injection The metabolism of Imipramine can be increased when combined with Tocilizumab.
Dalfampridine	Dalfampridine The risk or severity of seizure can be increased when Imipramine is combined with Dalfampridine.
Fingolimod	Fingolimod The metabolism of Fingolimod can be decreased when combined with Imipramine.
Eribulin Injection	Eribulin Injection The risk or severity of QTc prolongation can be increased when Eribulin is combined with Imipramine.
IncobotulinumtoxinA Injection	IncobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Botulinum toxin type A.
Cabazitaxel Injection	Cabazitaxel Injection The serum concentration of Imipramine can be increased when it is combined with Cabazitaxel.
Ceftaroline Injection	Ceftaroline Injection Ceftaroline fosamil may decrease the excretion rate of Imipramine which could result in a higher serum level.
Lurasidone	Lurasidone Imipramine may increase the hypotensive activities of Lurasidone.
Acetaminophen Injection	Acetaminophen Injection Imipramine may increase the hepatotoxic activities of Acetaminophen.
Vilazodone	Vilazodone The metabolism of Vilazodone can be decreased when combined with Imipramine.
Ipilimumab Injection	Ipilimumab Injection Imipramine may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
Denileukin Diftitox Injection	Denileukin Diftitox Injection Aldesleukin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Terbutaline Injection	Terbutaline Injection The therapeutic efficacy of Imipramine can be decreased when used in combination with Terbutaline.
Azilsartan	Azilsartan The risk or severity of adverse effects can be increased when Imipramine is combined with Azilsartan medoxomil.
Roflumilast	Roflumilast Imipramine may decrease the excretion rate of Roflumilast which could result in a higher serum level.
Linagliptin	Linagliptin The serum concentration of Linagliptin can be increased when it is combined with Imipramine.
Rilpivirine	Rilpivirine The metabolism of Imipramine can be decreased when combined with Rilpivirine.
Telaprevir	Telaprevir The serum concentration of Imipramine can be increased when it is combined with Glecaprevir.
Potassium Iodide	Potassium Iodide The risk or severity of Cardiac Arrhythmia can be increased when Potassium Iodide is combined with Imipramine.
Cyclophosphamide Injection	Cyclophosphamide Injection The metabolism of Cyclophosphamide can be decreased when combined with Imipramine.
Abiraterone	Abiraterone The serum concentration of Imipramine can be increased when it is combined with Abiraterone.
Triptorelin Injection	Triptorelin Injection The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Imipramine.
Rivaroxaban	Rivaroxaban The serum concentration of Rivaroxaban can be increased when it is combined with Imipramine.
Ticagrelor	Ticagrelor The serum concentration of Imipramine can be increased when it is combined with Ticagrelor.
Ruxolitinib	Ruxolitinib Imipramine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Vandetanib	Vandetanib The serum concentration of Vandetanib can be increased when it is combined with Imipramine.
Clobazam	Clobazam The metabolism of Imipramine can be decreased when combined with Clobazam.
Vemurafenib	Vemurafenib The serum concentration of Imipramine can be increased when it is combined with Vemurafenib.
Vismodegib	Vismodegib The metabolism of Imipramine can be decreased when combined with Vismodegib.
Ivacaftor	Ivacaftor The serum concentration of Imipramine can be increased when it is combined with Ivacaftor.
Deferiprone	Deferiprone Imipramine may decrease the excretion rate of Deferiprone which could result in a higher serum level.
Axitinib	Axitinib The metabolism of Imipramine can be decreased when combined with Axitinib.
Crizotinib	Crizotinib The serum concentration of Imipramine can be increased when it is combined with Crizotinib.
Cabergoline	Cabergoline Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Naloxone Injection	Naloxone Injection Imipramine may decrease the excretion rate of Naloxone which could result in a higher serum level.
Ambrisentan	Ambrisentan The serum concentration of Ambrisentan can be increased when it is combined with Imipramine.
Fondaparinux Injection	Fondaparinux Injection Imipramine may decrease the excretion rate of Fondaparinux which could result in a higher serum level.
Ezogabine	Ezogabine Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Carfilzomib Injection	Carfilzomib Injection The serum concentration of Imipramine can be increased when it is combined with Carfilzomib.
Iloprost	Iloprost The risk or severity of adverse effects can be increased when Imipramine is combined with Iloprost.
Enzalutamide	Enzalutamide The serum concentration of Imipramine can be increased when it is combined with Enzalutamide.
Mirabegron	Mirabegron The risk or severity of urinary retention can be increased when Imipramine is combined with Mirabegron.
Regorafenib	Regorafenib The serum concentration of Imipramine can be increased when it is combined with Regorafenib.
Linaclotide	Linaclotide The therapeutic efficacy of Linaclotide can be decreased when used in combination with Imipramine.
Teriflunomide	Teriflunomide The serum concentration of Imipramine can be decreased when it is combined with Teriflunomide.
Lorcaserin	Lorcaserin Imipramine may decrease the hypoglycemic activities of Mecasermin.
Teduglutide Injection	Teduglutide Injection Imipramine may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Bedaquiline	Bedaquiline The risk or severity of QTc prolongation can be increased when Imipramine is combined with Bedaquiline.
Alogliptin	Alogliptin The metabolism of Imipramine can be decreased when combined with Alogliptin.
Ponatinib	Ponatinib The metabolism of Imipramine can be decreased when combined with Ponatinib.
Pomalidomide	Pomalidomide The metabolism of Imipramine can be decreased when combined with Pomalidomide.
Ado-trastuzumab Emtansine Injection	Ado-trastuzumab Emtansine Injection The serum concentration of Imipramine can be increased when it is combined with Trastuzumab emtansine.
Apixaban	Apixaban The metabolism of Imipramine can be decreased when combined with Apixaban.
Canagliflozin	Canagliflozin The serum concentration of Canagliflozin can be increased when it is combined with Imipramine.
Methazolamide	Methazolamide Methazolamide may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy.
Dabrafenib	Dabrafenib The serum concentration of Imipramine can be decreased when it is combined with Dabrafenib.
Ospemifene	Ospemifene The metabolism of Imipramine can be decreased when combined with Ospemifene.
Trametinib	Trametinib Imipramine may decrease the excretion rate of Trametinib which could result in a higher serum level.
Dolutegravir	Dolutegravir The serum concentration of Imipramine can be increased when it is combined with Dolutegravir.
Afatinib	Afatinib The serum concentration of Imipramine can be increased when it is combined with Afatinib.
Levomilnacipran	Levomilnacipran The metabolism of Levomilnacipran can be decreased when combined with Imipramine.
Ertapenem Injection	Ertapenem Injection Ertapenem may decrease the excretion rate of Imipramine which could result in a higher serum level.
Vortioxetine	Vortioxetine The metabolism of Vortioxetine can be decreased when combined with Imipramine.
Perampanel	Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Ibrutinib	Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Imipramine.
Lomitapide	Lomitapide The serum concentration of Imipramine can be increased when it is combined with Lomitapide.
Avanafil	Avanafil The risk or severity of hypotension, dyspepsia, and headache can be increased when Avanafil is combined with Imipramine.
Ketorolac Injection	Ketorolac Injection Imipramine may decrease the excretion rate of Ketorolac which could result in a higher serum level.
Obinutuzumab Injection	Obinutuzumab Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Obinutuzumab.
Simeprevir	Simeprevir The serum concentration of Imipramine can be increased when it is combined with Simeprevir.
Sofosbuvir	Sofosbuvir The serum concentration of Sofosbuvir can be increased when it is combined with Imipramine.
Dapagliflozin	Dapagliflozin The metabolism of Imipramine can be decreased when combined with Dapagliflozin.
Apremilast	Apremilast The metabolism of Apremilast can be increased when combined with Imipramine.
Droxidopa	Droxidopa Imipramine may increase the vasopressor activities of Droxidopa.
Ceritinib	Ceritinib The risk or severity of QTc prolongation can be increased when Imipramine is combined with Ceritinib.
Siltuximab Injection	Siltuximab Injection The metabolism of Imipramine can be increased when combined with Siltuximab.
Albiglutide Injection	Albiglutide Injection Imipramine may decrease the hypoglycemic activities of Albiglutide.
Eslicarbazepine	Eslicarbazepine The metabolism of Imipramine can be decreased when combined with Eslicarbazepine.
Belinostat Injection	Belinostat Injection The metabolism of Imipramine can be increased when combined with Belinostat.
Idelalisib	Idelalisib The serum concentration of Imipramine can be increased when it is combined with Idelalisib.
Testosterone Injection	Testosterone Injection The metabolism of Testosterone can be decreased when combined with Imipramine.
Oritavancin Injection	Oritavancin Injection The metabolism of Imipramine can be decreased when combined with Oritavancin.
Empagliflozin	Empagliflozin Imipramine may decrease the hypoglycemic activities of Empagliflozin.
Vorapaxar	Vorapaxar The serum concentration of Imipramine can be increased when it is combined with Vorapaxar.
Hydrocodone	Hydrocodone Hydrocodone may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Suvorexant	Suvorexant Imipramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Dulaglutide Injection	Dulaglutide Injection Imipramine may decrease the hypoglycemic activities of Dulaglutide.
Edoxaban	Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Imipramine.
Peginterferon Beta-1a Injection	Peginterferon Beta-1a Injection The metabolism of Imipramine can be decreased when combined with Peginterferon beta-1a.
Olaparib	Olaparib The metabolism of Imipramine can be increased when combined with Olaparib.
Methamphetamine	Methamphetamine Metamfetamine may decrease the sedative and stimulatory activities of Imipramine.
Tasimelteon	Tasimelteon Tasimelteon may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Riociguat	Riociguat Imipramine may decrease the antihypertensive activities of Riociguat.
Pirfenidone	Pirfenidone The serum concentration of Pirfenidone can be increased when it is combined with Imipramine.
Nintedanib	Nintedanib The serum concentration of Imipramine can be increased when it is combined with Nintedanib.
Secukinumab Injection	Secukinumab Injection The metabolism of Imipramine can be increased when combined with Secukinumab.
Risperidone Injection	Risperidone Injection Imipramine may increase the hypotensive activities of Risperidone.
Palbociclib	Palbociclib The serum concentration of Imipramine can be increased when it is combined with Palbociclib.
Insulin Human Inhalation	Insulin Human Inhalation The metabolism of Imipramine can be increased when combined with Insulin human.
Lenvatinib	Lenvatinib The metabolism of Imipramine can be decreased when combined with Lenvatinib.
Naloxegol	Naloxegol The metabolism of Imipramine can be decreased when combined with Naloxegol.
Panobinostat	Panobinostat The metabolism of Imipramine can be decreased when combined with Panobinostat.
Dinutuximab Injection	Dinutuximab Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Dinutuximab.
Haloperidol Injection	Haloperidol Injection The serum concentration of Haloperidol can be increased when it is combined with Imipramine.
Ivabradine	Ivabradine Ivabradine may increase the QTc-prolonging activities of Imipramine.
Amiloride	Amiloride Amiloride may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy.
Isavuconazonium Injection	Isavuconazonium Injection The serum concentration of Imipramine can be increased when it is combined with Isavuconazonium.
Macitentan	Macitentan Imipramine may decrease the excretion rate of Macitentan which could result in a higher serum level.
Flibanserin	Flibanserin The serum concentration of Flibanserin can be increased when it is combined with Imipramine.
Rolapitant	Rolapitant The metabolism of Imipramine can be decreased when combined with Rolapitant.
Daclatasvir	Daclatasvir The serum concentration of Daclatasvir can be increased when it is combined with Imipramine.
Brexpiprazole	Brexpiprazole The metabolism of Brexpiprazole can be decreased when combined with Imipramine.
Ziprasidone Injection	Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Imipramine.
Cariprazine	Cariprazine The metabolism of Cariprazine can be decreased when combined with Imipramine.
Penicillin G Procaine Injection	Penicillin G Procaine Injection Imipramine may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Eluxadoline	Eluxadoline The risk or severity of constipation can be increased when Imipramine is combined with Eluxadoline.
Insulin Degludec (rDNA Origin) Injection	Insulin Degludec (rDNA Origin) Injection The metabolism of Imipramine can be increased when combined with Insulin degludec.
Cobimetinib	Cobimetinib The serum concentration of Imipramine can be increased when it is combined with Cobimetinib.
Trabectedin Injection	Trabectedin Injection The metabolism of Imipramine can be decreased when combined with Trabectedin.
Osimertinib	Osimertinib The serum concentration of Imipramine can be decreased when it is combined with Osimertinib.
Ixazomib	Ixazomib Imipramine may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Rifapentine	Rifapentine The metabolism of Imipramine can be increased when combined with Rifapentine.
Lesinurad	Lesinurad Imipramine may decrease the excretion rate of Lesinurad which could result in a higher serum level.
Amphotericin B Liposomal Injection	Amphotericin B Liposomal Injection Amphotericin B may decrease the excretion rate of Imipramine which could result in a higher serum level.
Dexamethasone Injection	Dexamethasone Injection The metabolism of Imipramine can be increased when combined with Dexamethasone.
Brivaracetam Injection	Brivaracetam Injection Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Venetoclax	Venetoclax The serum concentration of Imipramine can be increased when it is combined with Venetoclax.
Cobicistat	Cobicistat The serum concentration of Imipramine can be increased when it is combined with Cobicistat.
Midodrine	Midodrine Midodrine may increase the vasopressor activities of Imipramine.
Selexipag	Selexipag The serum concentration of Selexipag can be increased when it is combined with Imipramine.
Pimavanserin	Pimavanserin The risk or severity of adverse effects can be increased when Imipramine is combined with Pimavanserin.
Obeticholic Acid	Obeticholic Acid The risk or severity of adverse effects can be increased when Obeticholic acid is combined with Imipramine.
Diphenhydramine Injection	Diphenhydramine Injection The metabolism of Imipramine can be decreased when combined with Diphenhydramine.
Furosemide Injection	Furosemide Injection Imipramine may decrease the excretion rate of Furosemide which could result in a higher serum level.
Rucaparib	Rucaparib The metabolism of Imipramine can be decreased when combined with Rucaparib.
Lixisenatide Injection	Lixisenatide Injection Imipramine may decrease the hypoglycemic activities of Lixisenatide.
Ribociclib	Ribociclib The risk or severity of QTc prolongation can be increased when Imipramine is combined with Ribociclib.
Doxepin (Insomnia)	Doxepin (Insomnia) Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.
Plecanatide	Plecanatide The therapeutic efficacy of Plecanatide can be decreased when used in combination with Imipramine.
Deutetrabenazine	Deutetrabenazine The metabolism of Imipramine can be decreased when combined with Deutetrabenazine.
Valbenazine	Valbenazine The metabolism of Imipramine can be decreased when combined with Valbenazine.
Safinamide	Safinamide The metabolism of Imipramine can be decreased when combined with Safinamide.
Naldemedine	Naldemedine Imipramine may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Midostaurin	Midostaurin The metabolism of Imipramine can be decreased when combined with Midostaurin.
Neratinib	Neratinib The serum concentration of Imipramine can be increased when it is combined with Neratinib.
Enasidenib	Enasidenib The metabolism of Imipramine can be decreased when combined with Enasidenib.
Inotuzumab Ozogamicin Injection	Inotuzumab Ozogamicin Injection The serum concentration of Imipramine can be increased when it is combined with Inotuzumab ozogamicin.
Benznidazole	Benznidazole Imipramine may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Copanlisib Injection	Copanlisib Injection The metabolism of Copanlisib can be decreased when combined with Imipramine.
Delafloxacin	Delafloxacin The risk or severity of QTc prolongation can be increased when Imipramine is combined with Delafloxacin.
Betrixaban	Betrixaban The serum concentration of Imipramine can be increased when it is combined with Betrixaban.
Letermovir	Letermovir The metabolism of Imipramine can be decreased when combined with Letermovir.
Semaglutide Injection	Semaglutide Injection Imipramine may decrease the hypoglycemic activities of Semaglutide.
Tetrabenazine	Tetrabenazine The metabolism of Imipramine can be decreased when combined with Tetrabenazine.
Ertugliflozin	Ertugliflozin Imipramine may decrease the hypoglycemic activities of Ertugliflozin.
Buprenorphine Injection	Buprenorphine Injection Imipramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Apalutamide	Apalutamide The serum concentration of Imipramine can be increased when it is combined with Apalutamide.
Fostamatinib	Fostamatinib The risk or severity of hypotension, dyspepsia, and headache can be increased when Fostamatinib is combined with Imipramine.
Avatrombopag	Avatrombopag The serum concentration of Imipramine can be increased when it is combined with Avatrombopag.
Baricitinib	Baricitinib The serum concentration of Baricitinib can be increased when it is combined with Imipramine.
Lofexidine	Lofexidine The therapeutic efficacy of Imipramine can be increased when used in combination with Lofexidine.
Plazomicin Injection	Plazomicin Injection Imipramine may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Eliglustat	Eliglustat The metabolism of Eliglustat can be decreased when combined with Imipramine.
Encorafenib	Encorafenib The metabolism of Imipramine can be decreased when combined with Encorafenib.
Binimetinib	Binimetinib The metabolism of Binimetinib can be decreased when combined with Imipramine.
Ivosidenib	Ivosidenib The serum concentration of Ivosidenib can be increased when it is combined with Imipramine.
Lusutrombopag	Lusutrombopag The serum concentration of Imipramine can be increased when it is combined with Lusutrombopag.
Elagolix	Elagolix The metabolism of Imipramine can be decreased when combined with Elagolix.
Tafenoquine	Tafenoquine The metabolism of Imipramine can be decreased when combined with Tafenoquine.
Cannabidiol	Cannabidiol The risk or severity of adverse effects can be increased when Cannabidiol is combined with Imipramine.
Dacomitinib	Dacomitinib The metabolism of Imipramine can be decreased when combined with Dacomitinib.
Duvelisib	Duvelisib The serum concentration of Imipramine can be increased when it is combined with Duvelisib.
Omadacycline	Omadacycline The serum concentration of Imipramine can be increased when it is combined with Omadacycline.
Sarecycline	Sarecycline The serum concentration of Imipramine can be increased when it is combined with Sarecycline.
Stiripentol	Stiripentol The metabolism of Imipramine can be decreased when combined with Stiripentol.
Talazoparib	Talazoparib The serum concentration of Imipramine can be increased when it is combined with Talazoparib.
Gilteritinib	Gilteritinib The therapeutic efficacy of Imipramine can be decreased when used in combination with Gilteritinib.
Glasdegib	Glasdegib The serum concentration of Glasdegib can be increased when it is combined with Imipramine.
Lorlatinib	Lorlatinib The metabolism of Imipramine can be decreased when combined with Lorlatinib.
Larotrectinib	Larotrectinib The serum concentration of Imipramine can be increased when it is combined with Larotrectinib.
Paclitaxel (with albumin) Injection	Paclitaxel (with albumin) Injection The metabolism of Paclitaxel can be decreased when combined with Imipramine.
Rifamycin	Rifamycin The serum concentration of Imipramine can be increased when it is combined with Rifamycin.
Prucalopride	Prucalopride Imipramine may decrease the excretion rate of Prucalopride which could result in a higher serum level.
Magnesium Citrate	Magnesium Citrate The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Imipramine.
Emapalumab-lzsg Injection	Emapalumab-lzsg Injection The metabolism of Imipramine can be increased when combined with Emapalumab.
Siponimod	Siponimod The risk or severity of hypertension can be increased when Imipramine is combined with Siponimod.
Acyclovir Ophthalmic	Acyclovir Ophthalmic The metabolism of Acyclovir can be decreased when combined with Imipramine.
Erdafitinib	Erdafitinib The serum concentration of Imipramine can be increased when it is combined with Erdafitinib.
Esomeprazole Injection	Esomeprazole Injection The metabolism of Imipramine can be decreased when combined with Esomeprazole.
Alpelisib	Alpelisib The metabolism of Imipramine can be decreased when combined with Alpelisib.
Brexanolone Injection	Brexanolone Injection Brexanolone may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Solriamfetol	Solriamfetol The risk or severity of hypertension can be increased when Solriamfetol is combined with Imipramine.
Darolutamide	Darolutamide The serum concentration of Imipramine can be increased when it is combined with Darolutamide.
Triclabendazole	Triclabendazole The metabolism of Imipramine can be decreased when combined with Triclabendazole.
Entrectinib	Entrectinib The risk or severity of QTc prolongation can be increased when Imipramine is combined with Entrectinib.
Istradefylline	Istradefylline The metabolism of Istradefylline can be decreased when combined with Imipramine.
Pitolisant	Pitolisant The therapeutic efficacy of Pitolisant can be decreased when used in combination with Imipramine.
Fedratinib	Fedratinib The serum concentration of Fedratinib can be increased when it is combined with Imipramine.
Lefamulin	Lefamulin Lefamulin may increase the QTc-prolonging activities of Imipramine.
Phenytoin Injection	Phenytoin Injection The metabolism of Phenytoin can be decreased when combined with Imipramine.
Fosphenytoin Injection	Fosphenytoin Injection The metabolism of Imipramine can be increased when combined with Fosphenytoin.
Enfortumab vedotin-ejfv Injection	Enfortumab vedotin-ejfv Injection The serum concentration of Imipramine can be increased when it is combined with Enfortumab vedotin.
Zanubrutinib	Zanubrutinib The metabolism of Zanubrutinib can be decreased when combined with Imipramine.
Voxelotor	Voxelotor The metabolism of Voxelotor can be decreased when combined with Imipramine.
Lumateperone	Lumateperone Lumateperone may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Lasmiditan	Lasmiditan The risk or severity of serotonin syndrome can be increased when Imipramine is combined with Lasmiditan.
Ubrogepant	Ubrogepant The serum concentration of Imipramine can be increased when it is combined with Ubrogepant.
Tazemetostat	Tazemetostat The serum concentration of Imipramine can be increased when it is combined with Tazemetostat.
Cenobamate	Cenobamate The serum concentration of Cenobamate can be decreased when it is combined with Imipramine.
Selumetinib	Selumetinib The metabolism of Selumetinib can be decreased when combined with Imipramine.
Rimegepant	Rimegepant The serum concentration of Imipramine can be increased when it is combined with Rimegepant.
Tucatinib	Tucatinib The metabolism of Tucatinib can be decreased when combined with Imipramine.
Remdesivir Injection	Remdesivir Injection The serum concentration of Imipramine can be increased when it is combined with Remdesivir.
Ripretinib	Ripretinib The serum concentration of Imipramine can be increased when it is combined with Ripretinib.
Selpercatinib	Selpercatinib The risk or severity of hypertension can be increased when Imipramine is combined with Selpercatinib.
Capmatinib	Capmatinib The serum concentration of Imipramine can be increased when it is combined with Capmatinib.
Lemborexant	Lemborexant The serum concentration of Imipramine can be decreased when it is combined with Lemborexant.
Daratumumab and Hyaluronidase-fihj Injection	Daratumumab and Hyaluronidase-fihj Injection The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Imipramine.
Fenfluramine	Fenfluramine The risk or severity of serotonin syndrome can be increased when Fenfluramine is combined with Imipramine.
Fostemsavir	Fostemsavir The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Imipramine.
Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection	Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Imipramine.
Octreotide	Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Imipramine.
Belantamab Mafodotin-blmf Injection	Belantamab Mafodotin-blmf Injection The serum concentration of Imipramine can be increased when it is combined with Belantamab mafodotin.
Pralsetinib	Pralsetinib The serum concentration of Imipramine can be increased when it is combined with Pralsetinib.
Opicapone	Opicapone The metabolism of Imipramine can be increased when combined with Opicapone.
Satralizumab-mwge Injection	Satralizumab-mwge Injection The serum concentration of Imipramine can be decreased when it is combined with Satralizumab.
Naxitamab-gqgk Injection	Naxitamab-gqgk Injection The risk or severity of hypertension can be increased when Imipramine is combined with Naxitamab.
Relugolix	Relugolix The risk or severity of QTc prolongation can be increased when Relugolix is combined with Imipramine.
Progestin-Only (drospirenone) Oral Contraceptives	Progestin-Only (drospirenone) Oral Contraceptives Drospirenone may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy.
Viloxazine	Viloxazine The metabolism of Imipramine can be decreased when combined with Viloxazine.
Tobramycin Injection	Tobramycin Injection Tobramycin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Theophylline	Theophylline The metabolism of Imipramine can be decreased when combined with Theophylline.
Fenoprofen	Fenoprofen Imipramine may decrease the excretion rate of Fenoprofen which could result in a higher serum level.
Indomethacin	Indomethacin The metabolism of Imipramine can be decreased when combined with Indomethacin.
Mefenamic Acid	Mefenamic Acid Imipramine may decrease the excretion rate of Mefenamic acid which could result in a higher serum level.
Naproxen	Naproxen The metabolism of Naproxen can be decreased when combined with Imipramine.
Tolmetin	Tolmetin Imipramine may decrease the excretion rate of Tolmetin which could result in a higher serum level.
Sulindac	Sulindac Imipramine may decrease the excretion rate of Sulindac which could result in a higher serum level.
Trazodone	Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Imipramine.
Isotretinoin	Isotretinoin Imipramine may decrease the excretion rate of Isotretinoin which could result in a higher serum level.
Sucralfate	Sucralfate Sucralfate may decrease the excretion rate of Imipramine which could result in a higher serum level.
Hydroxyurea	Hydroxyurea The metabolism of Imipramine can be decreased when combined with Hydroxyurea.
Floxuridine	Floxuridine Floxuridine may decrease the excretion rate of Imipramine which could result in a higher serum level.
Phenobarbital	Phenobarbital The metabolism of Imipramine can be decreased when combined with Phenobarbital.
Metaxalone	Metaxalone Metaxalone may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Methotrexate Injection	Methotrexate Injection Methotrexate may decrease the excretion rate of Imipramine which could result in a higher serum level.
Levorphanol	Levorphanol The risk or severity of adverse effects can be increased when Imipramine is combined with Levorphanol.
Primidone	Primidone The metabolism of Imipramine can be increased when combined with Primidone.
Methsuximide	Methsuximide The metabolism of Methsuximide can be decreased when combined with Imipramine.
Diethylpropion	Diethylpropion Diethylpropion may decrease the sedative and stimulatory activities of Imipramine.
Chlorpromazine	Chlorpromazine Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Chlorpromazine.
Diazepam	Diazepam The metabolism of Imipramine can be decreased when combined with Diazepam.
Oxazepam	Oxazepam Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Flurazepam	Flurazepam Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Clorazepate	Clorazepate Clorazepic acid may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Lorazepam	Lorazepam Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Phenoxybenzamine	Phenoxybenzamine Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Phenoxybenzamine.
Carmustine	Carmustine The metabolism of Carmustine can be decreased when combined with Imipramine.
Amantadine	Amantadine The risk or severity of QTc prolongation can be increased when Imipramine is combined with Amantadine.
Codeine	Codeine The metabolism of Imipramine can be decreased when combined with Codeine.
Meprobamate	Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Imipramine.
Chlordiazepoxide	Chlordiazepoxide The risk or severity of adverse effects can be increased when Imipramine is combined with Chlordiazepoxide.
Bromocriptine	Bromocriptine Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine.
Metaproterenol	Metaproterenol The risk or severity of hypertension can be increased when Imipramine is combined with Orciprenaline.
Tranylcypromine	Tranylcypromine The metabolism of Tranylcypromine can be decreased when combined with Imipramine.
Phenelzine	Phenelzine The metabolism of Imipramine can be decreased when combined with Phenelzine.
Procarbazine	Procarbazine Procarbazine may increase the serotonergic activities of Imipramine.
Ergoloid Mesylates	Ergoloid Mesylates Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Tetracycline	Tetracycline Imipramine may decrease the excretion rate of Tetracycline which could result in a higher serum level.
Minocycline	Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Prochlorperazine	Prochlorperazine The metabolism of Imipramine can be decreased when combined with Prochlorperazine.
Thioridazine	Thioridazine Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Thioridazine.
Trifluoperazine	Trifluoperazine Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine.
Bleomycin	Bleomycin Bleomycin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Dapsone	Dapsone The metabolism of Imipramine can be decreased when combined with Dapsone.
Sulfadiazine	Sulfadiazine Imipramine may decrease the hypoglycemic activities of Sulfadiazine.
Oxycodone	Oxycodone The metabolism of Imipramine can be decreased when combined with Oxycodone.
Methadone	Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Imipramine.
Oxybutynin	Oxybutynin The metabolism of Oxybutynin can be decreased when combined with Imipramine.
Benztropine	Benztropine The metabolism of Imipramine can be decreased when combined with Benzatropine.
Maprotiline	Maprotiline The metabolism of Maprotiline can be decreased when combined with Imipramine.
Ibuprofen	Ibuprofen Imipramine may decrease the excretion rate of Ibuprofen which could result in a higher serum level.
Trihexyphenidyl	Trihexyphenidyl Imipramine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.
Orphenadrine	Orphenadrine Imipramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Perphenazine	Perphenazine The metabolism of Perphenazine can be decreased when combined with Imipramine.
Azathioprine	Azathioprine The metabolism of Azathioprine can be decreased when combined with Imipramine.
Fluphenazine	Fluphenazine The serum concentration of Imipramine can be increased when it is combined with Fluphenazine.
Phentermine	Phentermine Phentermine may decrease the sedative and stimulatory activities of Imipramine.
Methylphenidate	Methylphenidate The risk or severity of adverse effects can be increased when Methylphenidate is combined with Imipramine.
Amoxapine	Amoxapine Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Amoxapine.
Sulfasalazine	Sulfasalazine Imipramine may decrease the excretion rate of Sulfasalazine which could result in a higher serum level.
Hydrocortisone	Hydrocortisone The metabolism of Imipramine can be increased when combined with Hydrocortisone.
Doxorubicin	Doxorubicin The metabolism of Imipramine can be decreased when combined with Doxorubicin.
Mechlorethamine	Mechlorethamine The therapeutic efficacy of Imipramine can be decreased when used in combination with Mechlorethamine.
Dactinomycin	Dactinomycin The serum concentration of Imipramine can be increased when it is combined with Dactinomycin.
Pyridostigmine	Pyridostigmine The therapeutic efficacy of Imipramine can be decreased when used in combination with Pyridostigmine.
Phenazopyridine	Phenazopyridine Phenazopyridine may decrease the excretion rate of Imipramine which could result in a higher serum level.
Carbamazepine	Carbamazepine The metabolism of Imipramine can be increased when combined with Carbamazepine.
Molindone	Molindone The risk or severity of adverse effects can be increased when Imipramine is combined with Molindone.
Methyldopa	Methyldopa The therapeutic efficacy of Methyldopa can be decreased when used in combination with Imipramine.
Clonidine	Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Imipramine.
Prazosin	Prazosin Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Prazosin.
Hydralazine	Hydralazine Imipramine may decrease the excretion rate of Hydralazine which could result in a higher serum level.
Cimetidine	Cimetidine The metabolism of Imipramine can be decreased when combined with Cimetidine.
Gentamicin Injection	Gentamicin Injection Gentamicin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Warfarin	Warfarin The metabolism of Warfarin can be decreased when combined with Imipramine.
Clonazepam	Clonazepam Clonazepam may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Loperamide	Loperamide The metabolism of Imipramine can be decreased when combined with Loperamide.
Promethazine	Promethazine The metabolism of Imipramine can be decreased when combined with Promethazine.
Meclofenamate	Meclofenamate Imipramine may decrease the excretion rate of Meclofenamic acid which could result in a higher serum level.
Nitrofurantoin	Nitrofurantoin Imipramine may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
Griseofulvin	Griseofulvin The metabolism of Imipramine can be increased when combined with Griseofulvin.
Digoxin	Digoxin Digoxin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Loxapine	Loxapine The serum concentration of Imipramine can be increased when it is combined with Loxapine.
Chloroquine	Chloroquine The metabolism of Imipramine can be decreased when combined with Chloroquine.
Quinine	Quinine The metabolism of Imipramine can be decreased when combined with Quinine.
Ethosuximide	Ethosuximide Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Triamterene	Triamterene The metabolism of Triamterene can be decreased when combined with Imipramine.
Lactulose	Lactulose The therapeutic efficacy of Lactulose can be decreased when used in combination with Imipramine.
Sulfinpyrazone	Sulfinpyrazone The metabolism of Imipramine can be increased when combined with Sulfinpyrazone.
Chlorothiazide	Chlorothiazide Imipramine may increase the excretion rate of Chlorothiazide which could result in a lower serum level and potentially a reduction in efficacy.
Chlorthalidone	Chlorthalidone Imipramine may increase the excretion rate of Chlorthalidone which could result in a lower serum level and potentially a reduction in efficacy.
Metolazone	Metolazone Imipramine may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.
Isosorbide	Isosorbide Isosorbide may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy.
Clindamycin Injection	Clindamycin Injection Imipramine may increase the neurotoxic activities of Clindamycin.
Secobarbital	Secobarbital The metabolism of Imipramine can be increased when combined with Secobarbital.
Desipramine	Desipramine The metabolism of Desipramine can be decreased when combined with Imipramine.
Amitriptyline	Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Imipramine.
Probenecid	Probenecid The metabolism of Imipramine can be decreased when combined with Probenecid.
Quinidine	Quinidine Quinidine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine.
Procainamide	Procainamide The metabolism of Procainamide can be decreased when combined with Imipramine.
Isoniazid	Isoniazid The metabolism of Imipramine can be decreased when combined with Isoniazid.
Pyrazinamide	Pyrazinamide Pyrazinamide may decrease the excretion rate of Imipramine which could result in a higher serum level.
Rifampin	Rifampin The serum concentration of Imipramine can be decreased when it is combined with Rifampicin.
Disopyramide	Disopyramide The risk or severity of QTc prolongation can be increased when Imipramine is combined with Disopyramide.
Valproic Acid	Valproic Acid The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Imipramine.
Tamoxifen	Tamoxifen The metabolism of Imipramine can be decreased when combined with Tamoxifen.
Butabarbital	Butabarbital Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Levothyroxine	Levothyroxine The risk or severity of Cardiac Arrhythmia and CNS stimulation can be increased when Levothyroxine is combined with Imipramine.
Liothyronine	Liothyronine The risk or severity of Cardiac Arrhythmia can be increased when Liothyronine is combined with Imipramine.
Methimazole	Methimazole The risk or severity of Cardiac Arrhythmia can be increased when Methimazole is combined with Imipramine.
Propylthiouracil	Propylthiouracil The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Imipramine.
Chlorpropamide	Chlorpropamide Imipramine may decrease the hypoglycemic activities of Chlorpropamide.
Glucagon Injection	Glucagon Injection Imipramine may increase the gastrointestinal motility reducing activities of Glucagon.
Tolbutamide	Tolbutamide Imipramine may decrease the hypoglycemic activities of Tolbutamide.
Tolazamide	Tolazamide Imipramine may decrease the hypoglycemic activities of Tolazamide.
Dextromethorphan	Dextromethorphan The metabolism of Imipramine can be decreased when combined with Dextromethorphan.
Cyclobenzaprine	Cyclobenzaprine The risk or severity of CNS depression can be increased when Imipramine is combined with Cyclobenzaprine.
Niacin	Niacin The metabolism of Imipramine can be decreased when combined with Niacin.
Baclofen	Baclofen The risk or severity of CNS depression and hypotonia can be increased when Baclofen is combined with Imipramine.
Doxylamine	Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Cyproheptadine	Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Imipramine.
Clemastine	Clemastine The metabolism of Imipramine can be decreased when combined with Clemastine.
Chlorpheniramine	Chlorpheniramine The metabolism of Imipramine can be decreased when combined with Chlorpheniramine.
Brompheniramine	Brompheniramine Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Meclizine	Meclizine The metabolism of Imipramine can be decreased when combined with Meclizine.
Ethambutol	Ethambutol Ethambutol may decrease the excretion rate of Imipramine which could result in a higher serum level.
Methyclothiazide	Methyclothiazide Methyclothiazide may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy.
Hydrochlorothiazide	Hydrochlorothiazide Imipramine may decrease the excretion rate of Hydrochlorothiazide which could result in a higher serum level.
Dantrolene	Dantrolene Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Chlorzoxazone	Chlorzoxazone The metabolism of Imipramine can be decreased when combined with Chlorzoxazone.
Carisoprodol	Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Imipramine.
Methocarbamol	Methocarbamol Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Pyridoxine	Pyridoxine Pyridoxine may decrease the excretion rate of Imipramine which could result in a higher serum level.
Folic Acid	Folic Acid Folic acid may decrease the excretion rate of Imipramine which could result in a higher serum level.
Disulfiram	Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Imipramine.
Propranolol (Cardiovascular)	Propranolol (Cardiovascular) The serum concentration of Propranolol can be increased when it is combined with Imipramine.
Minoxidil	Minoxidil Imipramine may decrease the antihypertensive activities of Minoxidil.
Pseudoephedrine	Pseudoephedrine Pseudoephedrine may decrease the sedative and stimulatory activities of Imipramine.
Nortriptyline	Nortriptyline Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nortriptyline.
Spironolactone	Spironolactone Spironolactone may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy.
Amphotericin B Injection	Amphotericin B Injection Amphotericin B may decrease the excretion rate of Imipramine which could result in a higher serum level.
Phytonadione	Phytonadione Imipramine may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
Amikacin Injection	Amikacin Injection Amikacin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Nadolol	Nadolol The metabolism of Imipramine can be decreased when combined with Nadolol.
Butorphanol Injection	Butorphanol Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Butorphanol.
Nalbuphine Injection	Nalbuphine Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Nalbuphine.
Allopurinol	Allopurinol Allopurinol may decrease the excretion rate of Imipramine which could result in a higher serum level.
Oxytocin Injection	Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Imipramine.
Trimethobenzamide	Trimethobenzamide Trimethobenzamide may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Clomiphene	Clomiphene The serum concentration of Imipramine can be increased when it is combined with Clomifene.
Flavoxate	Flavoxate Imipramine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
Papaverine	Papaverine The risk or severity of QTc prolongation can be increased when Imipramine is combined with Papaverine.
Fluorouracil Injection	Fluorouracil Injection The metabolism of Fluorouracil can be decreased when combined with Imipramine.
Colchicine	Colchicine The metabolism of Imipramine can be decreased when combined with Colchicine.
Cefaclor	Cefaclor Cefaclor may decrease the excretion rate of Imipramine which could result in a higher serum level.
Cefadroxil	Cefadroxil Cefadroxil may decrease the excretion rate of Imipramine which could result in a higher serum level.
Cefazolin Injection	Cefazolin Injection Cefazolin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Cephalexin	Cephalexin Cephalexin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Cefoxitin Injection	Cefoxitin Injection Cefoxitin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Dacarbazine	Dacarbazine The metabolism of Dacarbazine can be decreased when combined with Imipramine.
Acetazolamide	Acetazolamide Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Cefotaxime Injection	Cefotaxime Injection Cefotaxime may decrease the excretion rate of Imipramine which could result in a higher serum level.
Calcitonin Salmon Injection	Calcitonin Salmon Injection The risk or severity of Cardiac Arrhythmia can be increased when Salmon calcitonin is combined with Imipramine.
Ketoconazole	Ketoconazole The metabolism of Imipramine can be decreased when combined with Ketoconazole.
Pyrantel	Pyrantel Pyrantel may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Thiotepa Injection	Thiotepa Injection The metabolism of Imipramine can be decreased when combined with Thiotepa.
Vincristine Injection	Vincristine Injection The metabolism of Vincristine can be decreased when combined with Imipramine.
Captopril	Captopril Imipramine may decrease the antihypertensive activities of Captopril.
Dipyridamole	Dipyridamole The risk or severity of hypotension, dyspepsia, and headache can be increased when Dipyridamole is combined with Imipramine.
Isoxsuprine	Isoxsuprine The risk or severity of hypertension can be increased when Imipramine is combined with Isoxsuprine.
Vinblastine	Vinblastine The metabolism of Imipramine can be decreased when combined with Vinblastine.
Ethacrynic Acid	Ethacrynic Acid Etacrynic acid may decrease the excretion rate of Imipramine which could result in a higher serum level.
Colistimethate Injection	Colistimethate Injection Colistimethate may decrease the excretion rate of Imipramine which could result in a higher serum level.
Metoprolol	Metoprolol The metabolism of Imipramine can be decreased when combined with Metoprolol.
Hydroxyzine	Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Imipramine.
Thiothixene	Thiothixene The risk or severity of adverse effects can be increased when Imipramine is combined with Thiothixene.
Aspirin	Aspirin The metabolism of Acetylsalicylic acid can be increased when combined with Imipramine.
Salsalate	Salsalate Imipramine may decrease the excretion rate of Salsalate which could result in a higher serum level.
Alprazolam	Alprazolam Alprazolam may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Temazepam	Temazepam Temazepam may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Triazolam	Triazolam Triazolam may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Dicyclomine	Dicyclomine Imipramine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
Hyoscyamine	Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Imipramine.
Propantheline	Propantheline Imipramine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
Trimethoprim	Trimethoprim Trimethoprim may decrease the excretion rate of Imipramine which could result in a higher serum level.
Diltiazem	Diltiazem The metabolism of Imipramine can be decreased when combined with Diltiazem.
Nifedipine	Nifedipine The metabolism of Imipramine can be decreased when combined with Nifedipine.
Timolol	Timolol The metabolism of Timolol can be decreased when combined with Imipramine.
Verapamil	Verapamil Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.
Atenolol	Atenolol The metabolism of Imipramine can be decreased when combined with Atenolol.
Pindolol	Pindolol The metabolism of Imipramine can be decreased when combined with Pindolol.
Cisplatin Injection	Cisplatin Injection The serum concentration of Cisplatin can be increased when it is combined with Imipramine.
Diflunisal	Diflunisal Imipramine may decrease the excretion rate of Diflunisal which could result in a higher serum level.
Piroxicam	Piroxicam Imipramine may decrease the excretion rate of Piroxicam which could result in a higher serum level.
Bumetanide	Bumetanide Bumetanide may decrease the excretion rate of Imipramine which could result in a higher serum level.
Streptozocin	Streptozocin The metabolism of Imipramine can be increased when combined with Streptozocin.
Etoposide	Etoposide The metabolism of Etoposide can be decreased when combined with Imipramine.
Glyburide	Glyburide The metabolism of Glyburide can be decreased when combined with Imipramine.
Glipizide	Glipizide Imipramine may decrease the hypoglycemic activities of Glipizide.
Indapamide	Indapamide Imipramine may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.
Amoxicillin	Amoxicillin Imipramine may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
Nafcillin Injection	Nafcillin Injection The metabolism of Imipramine can be increased when combined with Nafcillin.
Oxacillin Injection	Oxacillin Injection Imipramine may decrease the excretion rate of Oxacillin which could result in a higher serum level.
Pentoxifylline	Pentoxifylline The metabolism of Pentoxifylline can be decreased when combined with Imipramine.
Pentamidine Injection	Pentamidine Injection The metabolism of Imipramine can be decreased when combined with Pentamidine.
Ceftriaxone Injection	Ceftriaxone Injection Ceftriaxone may decrease the excretion rate of Imipramine which could result in a higher serum level.
Labetalol	Labetalol Labetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine.
Auranofin	Auranofin Imipramine may decrease the excretion rate of Auranofin which could result in a higher serum level.
Leuprolide Injection	Leuprolide Injection The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Imipramine.
Gemfibrozil	Gemfibrozil The metabolism of Imipramine can be decreased when combined with Gemfibrozil.
Guanabenz	Guanabenz The risk or severity of hypertension can be increased when Imipramine is combined with Guanabenz.
Dipivefrin Ophthalmic	Dipivefrin Ophthalmic Adefovir dipivoxil may decrease the excretion rate of Imipramine which could result in a higher serum level.
Ceftazidime Injection	Ceftazidime Injection Ceftazidime may decrease the excretion rate of Imipramine which could result in a higher serum level.
Ketoprofen	Ketoprofen Imipramine may decrease the excretion rate of Ketoprofen which could result in a higher serum level.
Cefotetan Injection	Cefotetan Injection Cefotetan may decrease the excretion rate of Imipramine which could result in a higher serum level.
Pimozide	Pimozide The metabolism of Pimozide can be decreased when combined with Imipramine.
Enalapril	Enalapril Imipramine may decrease the antihypertensive activities of Enalapril.
Flurbiprofen	Flurbiprofen Imipramine may decrease the excretion rate of Flurbiprofen which could result in a higher serum level.
Amiodarone	Amiodarone The serum concentration of Imipramine can be increased when it is combined with Amiodarone.
Aztreonam Injection	Aztreonam Injection Aztreonam may decrease the excretion rate of Imipramine which could result in a higher serum level.
Buspirone	Buspirone The metabolism of Buspirone can be decreased when combined with Imipramine.
Lovastatin	Lovastatin The metabolism of Imipramine can be decreased when combined with Lovastatin.
Ciprofloxacin	Ciprofloxacin The metabolism of Imipramine can be decreased when combined with Ciprofloxacin.
Mesalamine	Mesalamine Mesalazine may decrease the excretion rate of Imipramine which could result in a higher serum level.
Diclofenac	Diclofenac The metabolism of Diclofenac can be decreased when combined with Imipramine.
Fluoxetine	Fluoxetine The serum concentration of Fluoxetine can be increased when it is combined with Imipramine.
Nimodipine	Nimodipine The risk or severity of hypotension can be increased when Imipramine is combined with Nimodipine.
Interferon Alfa-2b Injection	Interferon Alfa-2b Injection The metabolism of Imipramine can be decreased when combined with Interferon alfa-2b.
Clozapine	Clozapine Clozapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine.
Estazolam	Estazolam Estazolam may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Idarubicin	Idarubicin The metabolism of Imipramine can be decreased when combined with Idarubicin.
Ofloxacin	Ofloxacin The metabolism of Imipramine can be decreased when combined with Ofloxacin.
Didanosine	Didanosine Imipramine may decrease the excretion rate of Didanosine which could result in a higher serum level.
Pentostatin Injection	Pentostatin Injection Imipramine may decrease the excretion rate of Pentostatin which could result in a higher serum level.
Clarithromycin	Clarithromycin The serum concentration of Clarithromycin can be increased when it is combined with Imipramine.
Benazepril	Benazepril Imipramine may decrease the antihypertensive activities of Benazepril.
Etodolac	Etodolac Imipramine may decrease the excretion rate of Etodolac which could result in a higher serum level.
Felodipine	Felodipine The metabolism of Imipramine can be decreased when combined with Felodipine.
Fosinopril	Fosinopril Imipramine may decrease the excretion rate of Fosinopril which could result in a higher serum level.
Nabumetone	Nabumetone The metabolism of Nabumetone can be decreased when combined with Imipramine.
Pravastatin	Pravastatin The serum concentration of Imipramine can be increased when it is combined with Pravastatin.
Quinapril	Quinapril Imipramine may decrease the antihypertensive activities of Quinapril.
Ramipril	Ramipril Imipramine may decrease the antihypertensive activities of Ramipril.
Simvastatin	Simvastatin The metabolism of Simvastatin can be decreased when combined with Imipramine.
Amlodipine	Amlodipine The risk or severity of hypotension can be increased when Imipramine is combined with Amlodipine.
Teniposide Injection	Teniposide Injection The metabolism of Imipramine can be decreased when combined with Teniposide.
Itraconazole	Itraconazole The serum concentration of Imipramine can be increased when it is combined with Itraconazole.
Lisinopril	Lisinopril Imipramine may decrease the excretion rate of Lisinopril which could result in a higher serum level.
Oxaprozin	Oxaprozin Imipramine may decrease the excretion rate of Oxaprozin which could result in a higher serum level.
Rifabutin	Rifabutin The metabolism of Imipramine can be increased when combined with Rifabutin.
Sotalol	Sotalol The metabolism of Sotalol can be decreased when combined with Imipramine.
Bisoprolol	Bisoprolol Imipramine may increase the orthostatic hypotensive activities of Bisoprolol.
Zolpidem	Zolpidem Zolpidem may increase the Decreased alertness activities of Imipramine.
Doxazosin	Doxazosin Doxazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine.
Terazosin	Terazosin Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.
Isradipine	Isradipine The risk or severity of QTc prolongation can be increased when Imipramine is combined with Isradipine.
Omeprazole	Omeprazole The metabolism of Imipramine can be decreased when combined with Omeprazole.
Cisapride	Cisapride The metabolism of Imipramine can be decreased when combined with Cisapride.
Gabapentin	Gabapentin The risk or severity of adverse effects can be increased when Imipramine is combined with Gabapentin.
Fluvastatin	Fluvastatin The metabolism of Imipramine can be decreased when combined with Fluvastatin.
Venlafaxine	Venlafaxine The metabolism of Imipramine can be decreased when combined with Venlafaxine.
Nizatidine	Nizatidine The therapeutic efficacy of Imipramine can be decreased when used in combination with Nizatidine.
Stavudine	Stavudine Imipramine may increase the neurotoxic activities of Stavudine.
Fluvoxamine	Fluvoxamine The metabolism of Imipramine can be decreased when combined with Fluvoxamine.
Nefazodone	Nefazodone Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nefazodone.
Lamotrigine	Lamotrigine Imipramine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.
Losartan	Losartan The metabolism of Imipramine can be decreased when combined with Losartan.
Valacyclovir	Valacyclovir Valaciclovir may decrease the excretion rate of Imipramine which could result in a higher serum level.
Tramadol	Tramadol The risk or severity of serotonin syndrome can be increased when Imipramine is combined with Tramadol.
Vinorelbine Injection	Vinorelbine Injection The metabolism of Imipramine can be decreased when combined with Vinorelbine.
Carboplatin Injection	Carboplatin Injection Carboplatin may decrease the excretion rate of Imipramine which could result in a higher serum level.
Moexipril	Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Imipramine.
Lansoprazole	Lansoprazole The metabolism of Imipramine can be decreased when combined with Lansoprazole.
Ifosfamide Injection	Ifosfamide Injection The metabolism of Ifosfamide can be decreased when combined with Imipramine.
Nicardipine	Nicardipine Nicardipine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine.
Bupropion	Bupropion The risk or severity of seizure can be increased when Bupropion is combined with Imipramine.
Ticlopidine	Ticlopidine The metabolism of Imipramine can be decreased when combined with Ticlopidine.
Saquinavir	Saquinavir The serum concentration of Imipramine can be increased when it is combined with Saquinavir.
Metformin	Metformin Imipramine may decrease the hypoglycemic activities of Metformin.
Nisoldipine	Nisoldipine The risk or severity of hypotension can be increased when Nisoldipine is combined with Imipramine.
Lamivudine	Lamivudine The serum concentration of Lamivudine can be increased when it is combined with Imipramine.
Riluzole	Riluzole The metabolism of Riluzole can be decreased when combined with Imipramine.
Amifostine Injection	Amifostine Injection The risk or severity of adverse effects can be increased when Imipramine is combined with Amifostine.
Acarbose	Acarbose Imipramine may decrease the hypoglycemic activities of Acarbose.
Glimepiride	Glimepiride Imipramine may decrease the hypoglycemic activities of Glimepiride.
Gemcitabine Injection	Gemcitabine Injection The serum concentration of Imipramine can be increased when it is combined with Gemcitabine.
Indinavir	Indinavir The metabolism of Imipramine can be decreased when combined with Indinavir.
Ritonavir	Ritonavir The serum concentration of Imipramine can be increased when it is combined with Ritonavir.
Docetaxel Injection	Docetaxel Injection The metabolism of Docetaxel can be decreased when combined with Imipramine.
Cidofovir Injection	Cidofovir Injection Cidofovir may decrease the excretion rate of Imipramine which could result in a higher serum level.
Meropenem Injection	Meropenem Injection Imipramine may decrease the excretion rate of Meropenem which could result in a higher serum level.
Clomipramine	Clomipramine The metabolism of Clomipramine can be decreased when combined with Imipramine.
Zafirlukast	Zafirlukast The metabolism of Imipramine can be decreased when combined with Zafirlukast.
Fosfomycin	Fosfomycin Imipramine may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
Mirtazapine	Mirtazapine Imipramine may increase the serotonergic activities of Mirtazapine.
Trandolapril	Trandolapril Imipramine may decrease the antihypertensive activities of Trandolapril.
Topiramate	Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Imipramine is combined with Topiramate.
Zileuton	Zileuton The metabolism of Zileuton can be decreased when combined with Imipramine.
Valsartan	Valsartan Imipramine may decrease the antihypertensive activities of Valsartan.
Insulin Lispro Injection	Insulin Lispro Injection The metabolism of Imipramine can be increased when combined with Insulin lispro.
Pramipexole	Pramipexole Imipramine may increase the sedative activities of Pramipexole.
Donepezil	Donepezil The therapeutic efficacy of Imipramine can be decreased when used in combination with Donepezil.
Nelfinavir	Nelfinavir The metabolism of Imipramine can be decreased when combined with Nelfinavir.
Fexofenadine	Fexofenadine The serum concentration of Imipramine can be increased when it is combined with Fexofenadine.
Azithromycin	Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Imipramine.
Loratadine	Loratadine Imipramine may increase the anticholinergic activities of Loratadine.
Carvedilol	Carvedilol Carvedilol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine.
Nilutamide	Nilutamide The metabolism of Imipramine can be decreased when combined with Nilutamide.
Flutamide	Flutamide The metabolism of Flutamide can be decreased when combined with Imipramine.
Selegiline	Selegiline The metabolism of Selegiline can be decreased when combined with Imipramine.
Bicalutamide	Bicalutamide The metabolism of Imipramine can be decreased when combined with Bicalutamide.
Sertraline	Sertraline The metabolism of Sertraline can be decreased when combined with Imipramine.
Propafenone	Propafenone The metabolism of Imipramine can be decreased when combined with Propafenone.
Letrozole	Letrozole The metabolism of Imipramine can be decreased when combined with Letrozole.
Raloxifene	Raloxifene The metabolism of Imipramine can be decreased when combined with Raloxifene.
Irbesartan	Irbesartan Imipramine may decrease the antihypertensive activities of Irbesartan.
Tamsulosin	Tamsulosin Tamsulosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine.
Ropinirole	Ropinirole The risk or severity of adverse effects can be increased when Imipramine is combined with Ropinirole.
Finasteride	Finasteride The metabolism of Finasteride can be decreased when combined with Imipramine.
Quetiapine	Quetiapine Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Quetiapine.
Cefepime Injection	Cefepime Injection Cefepime may decrease the excretion rate of Imipramine which could result in a higher serum level.
Cefprozil	Cefprozil Cefprozil may decrease the excretion rate of Imipramine which could result in a higher serum level.
Cefpodoxime	Cefpodoxime Cefpodoxime may decrease the excretion rate of Imipramine which could result in a higher serum level.
Cetirizine	Cetirizine Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Paroxetine	Paroxetine The metabolism of Paroxetine can be decreased when combined with Imipramine.
Tolcapone	Tolcapone Tolcapone may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Citalopram	Citalopram Imipramine may increase the QTc-prolonging activities of Citalopram.
Capecitabine	Capecitabine Imipramine may decrease the excretion rate of Capecitabine which could result in a higher serum level.
Efavirenz	Efavirenz The metabolism of Imipramine can be increased when combined with Efavirenz.
Abacavir	Abacavir Imipramine may decrease the excretion rate of Abacavir which could result in a higher serum level.
Sildenafil	Sildenafil The metabolism of Imipramine can be decreased when combined with Sildenafil.
Pioglitazone	Pioglitazone Imipramine may decrease the hypoglycemic activities of Pioglitazone.
Celecoxib	Celecoxib The metabolism of Imipramine can be decreased when combined with Celecoxib.
Rosiglitazone	Rosiglitazone The metabolism of Imipramine can be decreased when combined with Rosiglitazone.
Tolterodine	Tolterodine The metabolism of Imipramine can be decreased when combined with Tolterodine.
Thalidomide	Thalidomide Imipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Oseltamivir	Oseltamivir Oseltamivir may decrease the excretion rate of Imipramine which could result in a higher serum level.
Balsalazide	Balsalazide Imipramine may decrease the excretion rate of Balsalazide which could result in a higher serum level.
Nateglinide	Nateglinide The metabolism of Imipramine can be decreased when combined with Nateglinide.
Galantamine	Galantamine The metabolism of Imipramine can be decreased when combined with Galantamine.
Levetiracetam	Levetiracetam Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Rabeprazole	Rabeprazole The metabolism of Imipramine can be decreased when combined with Rabeprazole.
Terbinafine	Terbinafine The metabolism of Imipramine can be decreased when combined with Terbinafine.